Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

Launch of TransCon™ PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024TransCon CNP pivotal App...

Related Keywords

Denmark ,Copenhagen ,Køavn ,Germany ,Austria ,United States ,Ascendis Pharma ,Melinda Baker ,Tim Lee ,Jan Mikkelsen ,Eyconis Inc ,Patti Bank ,Exchange Commission ,Chief Executive ,Europe Direct ,International Markets ,Endocrinology Rare Disease ,Biologics License Application ,Prescription Drug User Fee Act ,New Drug Application ,Investigational New Drug ,Outlook Based ,Current Plans ,Full Year ,Ascendi Annual Report ,Comprehensive Income ,